Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer

The BIG 1-98 trial

Diana Crivellari, Zhuoxin Sun, Alan S. Coates, Karen N. Price, Beat Thürlimann, Henning Mouridsen, Louis Mauriac, John F. Forbes, Robert J. Paridaens, Monica Castiglione-Gertsch, Richard D. Gelber, Marco Colleoni, István Láng, Lucia Del Mastro, Laurence Gladieff, Manuela Rabaglio, Ian E. Smith, Jacquie H. Chirgwin, Aron Goldhirsch

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Purpose: To explore potential differences in efficacy, treatment completion, and adverse events (AEs) in elderly women receiving adjuvant tamoxifen or letrozole for five years in the Breast International Group (BIG) 1-98 trial. Methods: This report includes the 4,922 patients allocated to 5 years of letrozole or tamoxifen in the BIG 1-98 trial. The median follow-up was 40.4 months. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis was used to examine the patterns of differences in disease-free survival and incidences of AEs according to age. In addition, three categoric age groups were defined: "younger postmenopausal" patients were younger than 65 years (n = 3,127), "older" patients were 65 to 74 years old (n = 1,500), and "elderly" patients were 75 years of age or older (n = 295). Results: Efficacy results for subpopulations defined by age were similar to the overall trial results: Letrozole significantly improved disease-free survival (DFS), the primary end point, compared with tamoxifen. Elderly patients were less likely to complete trial treatment, but at rates that were similar in the two treatment groups. The incidence of bone fractures, observed more often in the letrozole group, did not differ by age. In elderly patients, letrozole had a significantly higher incidence of any grade 3 to 5 protocol-specified non-fracture AE compared with tamoxifen (P = .002), but differences were not significant for thromboembolic or cardiac AEs. Conclusion: Adjuvant treatment with letrozole had superior efficacy (DFS) compared with tamoxifen in all age groups. On the basis of a small number of patients older than 75 years (6%), age per se should not unduly affect the choice of adjuvant endocrine therapy.

Original languageEnglish
Pages (from-to)1972-1979
Number of pages8
JournalJournal of Clinical Oncology
Volume26
Issue number12
DOIs
Publication statusPublished - 2008

Fingerprint

letrozole
Tamoxifen
Breast Neoplasms
Disease-Free Survival
Incidence
Breast
Age Groups
Therapeutics
Bone Fractures

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer : The BIG 1-98 trial. / Crivellari, Diana; Sun, Zhuoxin; Coates, Alan S.; Price, Karen N.; Thürlimann, Beat; Mouridsen, Henning; Mauriac, Louis; Forbes, John F.; Paridaens, Robert J.; Castiglione-Gertsch, Monica; Gelber, Richard D.; Colleoni, Marco; Láng, István; Del Mastro, Lucia; Gladieff, Laurence; Rabaglio, Manuela; Smith, Ian E.; Chirgwin, Jacquie H.; Goldhirsch, Aron.

In: Journal of Clinical Oncology, Vol. 26, No. 12, 2008, p. 1972-1979.

Research output: Contribution to journalArticle

Crivellari, D, Sun, Z, Coates, AS, Price, KN, Thürlimann, B, Mouridsen, H, Mauriac, L, Forbes, JF, Paridaens, RJ, Castiglione-Gertsch, M, Gelber, RD, Colleoni, M, Láng, I, Del Mastro, L, Gladieff, L, Rabaglio, M, Smith, IE, Chirgwin, JH & Goldhirsch, A 2008, 'Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The BIG 1-98 trial', Journal of Clinical Oncology, vol. 26, no. 12, pp. 1972-1979. https://doi.org/10.1200/JCO.2007.14.0459
Crivellari, Diana ; Sun, Zhuoxin ; Coates, Alan S. ; Price, Karen N. ; Thürlimann, Beat ; Mouridsen, Henning ; Mauriac, Louis ; Forbes, John F. ; Paridaens, Robert J. ; Castiglione-Gertsch, Monica ; Gelber, Richard D. ; Colleoni, Marco ; Láng, István ; Del Mastro, Lucia ; Gladieff, Laurence ; Rabaglio, Manuela ; Smith, Ian E. ; Chirgwin, Jacquie H. ; Goldhirsch, Aron. / Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer : The BIG 1-98 trial. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 12. pp. 1972-1979.
@article{c580283262c34e91b7e32199fc6fb8a8,
title = "Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The BIG 1-98 trial",
abstract = "Purpose: To explore potential differences in efficacy, treatment completion, and adverse events (AEs) in elderly women receiving adjuvant tamoxifen or letrozole for five years in the Breast International Group (BIG) 1-98 trial. Methods: This report includes the 4,922 patients allocated to 5 years of letrozole or tamoxifen in the BIG 1-98 trial. The median follow-up was 40.4 months. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis was used to examine the patterns of differences in disease-free survival and incidences of AEs according to age. In addition, three categoric age groups were defined: {"}younger postmenopausal{"} patients were younger than 65 years (n = 3,127), {"}older{"} patients were 65 to 74 years old (n = 1,500), and {"}elderly{"} patients were 75 years of age or older (n = 295). Results: Efficacy results for subpopulations defined by age were similar to the overall trial results: Letrozole significantly improved disease-free survival (DFS), the primary end point, compared with tamoxifen. Elderly patients were less likely to complete trial treatment, but at rates that were similar in the two treatment groups. The incidence of bone fractures, observed more often in the letrozole group, did not differ by age. In elderly patients, letrozole had a significantly higher incidence of any grade 3 to 5 protocol-specified non-fracture AE compared with tamoxifen (P = .002), but differences were not significant for thromboembolic or cardiac AEs. Conclusion: Adjuvant treatment with letrozole had superior efficacy (DFS) compared with tamoxifen in all age groups. On the basis of a small number of patients older than 75 years (6{\%}), age per se should not unduly affect the choice of adjuvant endocrine therapy.",
author = "Diana Crivellari and Zhuoxin Sun and Coates, {Alan S.} and Price, {Karen N.} and Beat Th{\"u}rlimann and Henning Mouridsen and Louis Mauriac and Forbes, {John F.} and Paridaens, {Robert J.} and Monica Castiglione-Gertsch and Gelber, {Richard D.} and Marco Colleoni and Istv{\'a}n L{\'a}ng and {Del Mastro}, Lucia and Laurence Gladieff and Manuela Rabaglio and Smith, {Ian E.} and Chirgwin, {Jacquie H.} and Aron Goldhirsch",
year = "2008",
doi = "10.1200/JCO.2007.14.0459",
language = "English",
volume = "26",
pages = "1972--1979",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer

T2 - The BIG 1-98 trial

AU - Crivellari, Diana

AU - Sun, Zhuoxin

AU - Coates, Alan S.

AU - Price, Karen N.

AU - Thürlimann, Beat

AU - Mouridsen, Henning

AU - Mauriac, Louis

AU - Forbes, John F.

AU - Paridaens, Robert J.

AU - Castiglione-Gertsch, Monica

AU - Gelber, Richard D.

AU - Colleoni, Marco

AU - Láng, István

AU - Del Mastro, Lucia

AU - Gladieff, Laurence

AU - Rabaglio, Manuela

AU - Smith, Ian E.

AU - Chirgwin, Jacquie H.

AU - Goldhirsch, Aron

PY - 2008

Y1 - 2008

N2 - Purpose: To explore potential differences in efficacy, treatment completion, and adverse events (AEs) in elderly women receiving adjuvant tamoxifen or letrozole for five years in the Breast International Group (BIG) 1-98 trial. Methods: This report includes the 4,922 patients allocated to 5 years of letrozole or tamoxifen in the BIG 1-98 trial. The median follow-up was 40.4 months. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis was used to examine the patterns of differences in disease-free survival and incidences of AEs according to age. In addition, three categoric age groups were defined: "younger postmenopausal" patients were younger than 65 years (n = 3,127), "older" patients were 65 to 74 years old (n = 1,500), and "elderly" patients were 75 years of age or older (n = 295). Results: Efficacy results for subpopulations defined by age were similar to the overall trial results: Letrozole significantly improved disease-free survival (DFS), the primary end point, compared with tamoxifen. Elderly patients were less likely to complete trial treatment, but at rates that were similar in the two treatment groups. The incidence of bone fractures, observed more often in the letrozole group, did not differ by age. In elderly patients, letrozole had a significantly higher incidence of any grade 3 to 5 protocol-specified non-fracture AE compared with tamoxifen (P = .002), but differences were not significant for thromboembolic or cardiac AEs. Conclusion: Adjuvant treatment with letrozole had superior efficacy (DFS) compared with tamoxifen in all age groups. On the basis of a small number of patients older than 75 years (6%), age per se should not unduly affect the choice of adjuvant endocrine therapy.

AB - Purpose: To explore potential differences in efficacy, treatment completion, and adverse events (AEs) in elderly women receiving adjuvant tamoxifen or letrozole for five years in the Breast International Group (BIG) 1-98 trial. Methods: This report includes the 4,922 patients allocated to 5 years of letrozole or tamoxifen in the BIG 1-98 trial. The median follow-up was 40.4 months. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis was used to examine the patterns of differences in disease-free survival and incidences of AEs according to age. In addition, three categoric age groups were defined: "younger postmenopausal" patients were younger than 65 years (n = 3,127), "older" patients were 65 to 74 years old (n = 1,500), and "elderly" patients were 75 years of age or older (n = 295). Results: Efficacy results for subpopulations defined by age were similar to the overall trial results: Letrozole significantly improved disease-free survival (DFS), the primary end point, compared with tamoxifen. Elderly patients were less likely to complete trial treatment, but at rates that were similar in the two treatment groups. The incidence of bone fractures, observed more often in the letrozole group, did not differ by age. In elderly patients, letrozole had a significantly higher incidence of any grade 3 to 5 protocol-specified non-fracture AE compared with tamoxifen (P = .002), but differences were not significant for thromboembolic or cardiac AEs. Conclusion: Adjuvant treatment with letrozole had superior efficacy (DFS) compared with tamoxifen in all age groups. On the basis of a small number of patients older than 75 years (6%), age per se should not unduly affect the choice of adjuvant endocrine therapy.

UR - http://www.scopus.com/inward/record.url?scp=42949164467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949164467&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.14.0459

DO - 10.1200/JCO.2007.14.0459

M3 - Article

VL - 26

SP - 1972

EP - 1979

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -